AngioDynamics

AngioDynamics R&D per Employee

The R&D Spending per Employee of AngioDynamics (ANGO) as of Sep 20, 2026 is 46,593.35 USD. In the previous year, R&D Spending per Employee was 41,490.51 USD — a change of 12.30% (higher).

R&D per Employee

46,593.35USD

YoY

12.30%

Last updated:

R&D Spending per Employee of AngioDynamics is 2026 46,593.35 USD. R&D Spending per Employee of AngioDynamics was 2025 41,490.51 USD. It decreases by 12.30% higher compared to the previous year.

The AngioDynamics R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
46,574.37 USD
Jan 1, 2020
46,965.19 USD
Jan 1, 2021
57,579.11 USD
Jan 1, 2022
48,637.66 USD
Jan 1, 2023
47,283.23 USD
Jan 1, 2024
49,860.76 USD
Jan 1, 2025
41,490.51 USD
Jan 1, 2026
46,593.35 USD
The AngioDynamics R&D per Employee history
YEARR&D per EmployeeYoY
46,593.35USD+12.30%
41,490.51USD-16.79%
49,860.76USD+5.45%
47,283.23USD-2.78%
48,637.66USD-15.53%
57,579.11USD+22.60%
46,965.19USD+0.84%
46,574.37USD+15.62%
40,283.23USD+0.75%
39,982.59USD+0.57%
39,756.33USD-6.70%
42,612.34USD-2.10%
43,528.48USD
Access this data via the Eulerpool API

AngioDynamics Stock analysis

What does AngioDynamics do? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AngioDynamics stock

R&D Spending per Employee of AngioDynamics is 46,593.35 USD in 2026.

R&D Spending per Employee of AngioDynamics changed from 41,490.51 USD to 46,593.35 USD, representing a 12.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee AngioDynamics since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's AngioDynamics historically and in real time.

Access this data via the Eulerpool API

Workforce — AngioDynamics

All Key Metrics — AngioDynamics